Cell therapy (Gene-edited cells) · Gene editing · developed by Vor Biopharma
Tremtelectogene empogeditemcel is an allogeneic, HLA-matched cell therapy of CD34-positive hematopoietic stem and progenitor cells (HSPCs) gene-edited with CRISPR-Cas9 to remove CD33. It is studied to improve hematopoietic recovery after hematopoietic cell transplantation and to protect cells from CD33-targeted chemotherapy in acute myeloid leukemia and myelodysplastic syndromes.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT04849910 | Phase 1/2 | Leukemia, Myeloid, Acute | Terminated | VOR |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Leukemia, Myeloid, AcuteMyelodysplastic Syndromes
Updated Oct 3, 2026. Something wrong or missing? Report it on the VOR page.
See VOR's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
VOR catalysts and pipeline →